Aspromonte N, Gulizia MM, Di Lenarda A, et al. ANMCO/SIC Consensus Document: cardiology networks for outpatient heart failure care. Eur Heart J Suppl. 2017;19(Suppl D):D89–101.

Article  PubMed  PubMed Central  Google Scholar 

Tavazzi L, Senni M, Metra M, et al. INHF (Italian Network on Heart Failure) Outcome Investigators. Multicenter prospective observational study on acute and chronic heart failure: one-year follow-up results of IN-HF (Italian Network on Heart Failure) outcome registry. Circ Heart Fail. 2013;6:473–81.

Article  CAS  PubMed  Google Scholar 

D’Elia E, Stamerra CA, Vecchi A, Duino V, Grosu A, Abete R, Baio P, Gori M, Gavazzi A, Ferri C, Senni M. Association between sleep disordered breathing, neurocognitive impairment and diastolic function in acute heart failure patients: an insight after the vulnerable phase of the hospitalization. Intern Emerg Med. 2021;16(2):369–77. https://doi.org/10.1007/s11739-020-02397-x.

Article  PubMed  Google Scholar 

Stamerra CA, D’Elia E, Gori M, Roncali F, Cereda A, Gavazzi A, Ferri C, Senni M. Red cell distribution width (RDW) is correlated to time of oxygen desaturation < 90% and length of sleep apneas in patients with sleep disorder breathing (SDB) and acute heart failure with preserved ejection fraction (HFpEF). Front Cardiovasc Med. 2023;3(10):1045702.

Article  Google Scholar 

McDonagh TA, Metra M, Adamo M; ESC Scientific Document Group et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599–3726. The ESC guidelines represent the cornerstone of HF treatment.

Mebazaa A, Davison B, Chioncel O, Cohen-Solal A, Diaz R, Filippatos G, Metra M, Ponikowski P, Sliwa K, Voors AA, Edwards C, Novosadova M, Takagi K, Damasceno A, Saidu H, Gayat E, Pang PS, Celutkiene J, Cotter G. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet. 2022;400(10367):1938–52.

Article  CAS  PubMed  Google Scholar 

Bender AT, Beavo JA. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev. 2006;58:488–520.

Article  CAS  PubMed  Google Scholar 

Fesenko EE, Kolesnikov SS, Lyubarsky AL. Induction by cyclic GMP of cationic conductance in plasma membrane of retinal rod outer segment. Nature. 1985;313:310–3.

Article  CAS  PubMed  Google Scholar 

Krüger M, Kötter S, Grützner A, Lang P, Andresen C, Redfield MM, Butt E, dos Remedios CG, Linke WA. Protein kinase G modulates human myocardial passive stiffness by phosphorylation of the titin springs. Circ Res. 2009;104:87–94.

Article  PubMed  Google Scholar 

Kovács Á, Alogna A, Post H, Hamdani N. Is enhancing cGMP-PKG signalling a promising therapeutic target for heart failure with preserved ejection fraction? Neth Heart J. 2016;24:268–74.

Article  PubMed  PubMed Central  Google Scholar 

Tsai EJ, Kass DA. Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics. Pharmacol Ther. 2009;122:216–38.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Beuve A. Thiol-based redox modulation of soluble guanylyl cyclase, the nitric oxide receptor. Antioxid Redox Signal. 2017;26:137–49.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sutton AJ, Abrams KR, Jones DR, Jones DR, Sheldon TA, Song F. Methods for meta-analysis in medical research: Wiley Chichester; 2000.

Borenstein M. Comprehensive meta‐analysis software. Systematic reviews in health research: meta‐analysis in context. 2022:535–48.

Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5(1):1–10.

Article  Google Scholar 

Sahebkar A, Serban C, Ursoniu S, Wong ND, Muntner P, Graham IM, Mikhailidis DP, Rizzo M, Rysz J, Sperling LS, Lip GY, Banach M. Lipid and Blood Pressure Meta-analysis Collaboration Group. Lack of efficacy of resveratrol on C-reactive protein and selected cardiovascular risk factors–Results from a systematic review and meta-analysis of randomized controlled trials. Int J Cardiol. 2015;189:47–55. https://doi.org/10.1016/j.ijcard.2015.04.008.

Article  PubMed  Google Scholar 

Sahebkar A. Effects of resveratrol supplementation on plasma lipids: a systematic review and meta-analysis of randomized controlled trials. Nutr Rev. 2013;71(12):822–35. https://doi.org/10.1111/nure.12081.

Article  PubMed  Google Scholar 

Duval S, Tweedie R. Trim and fill: a simple funnel-plot–based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56(2):455–63.

Article  CAS  PubMed  Google Scholar 

Dachs TM, Duca F, Rettl R, Binder-Rodriguez C, Dalos D, Ligios LC, et al. Riociguat in pulmonary hypertension and heart failure with preserved ejection fraction: the haemoDYNAMIC trial. Eur Heart J. 2022;43(36):3402–13.

Article  PubMed  PubMed Central  Google Scholar 

Armstrong PW, Roessig L, Patel MJ, Anstrom KJ, Butler J, Voors AA, Lam CSP, Ponikowski P, Temple T, Pieske B, Ezekowitz J, Hernandez AF, Koglin J, O'Connor CM. (2018) A multicenter, randomized, double-blind, placebo-controlled trial of the efficacy and safety of the oral soluble guanylate cyclase stimulator: the VICTORIA trial. JACC Heart Fail 6(2):96–104. Based on the VICTORIA trials’ findings, vericiguat is currently recommended by both the European and American HF guidelines for HFrEF patients.

Armstrong PW, Lam CS, Anstrom KJ, Ezekowitz J, Hernandez AF, O’Connor CM, et al. Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction: the VITALITY-HFpEF randomized clinical trial. JAMA. 2020;324(15):1512–21.

Article  CAS  PubMed  Google Scholar 

Udelson JE, Lewis GD, Shah SJ, Zile MR, Redfield MM, Burnett J, et al. Effect of praliciguat on peak rate of oxygen consumption in patients with heart failure with preserved ejection fraction: the CAPACITY HFpEF randomized clinical trial. JAMA. 2020;324(15):1522–31.

Article  PubMed  PubMed Central  Google Scholar 

Pieske B, Maggioni AP, Lam CS, Pieske-Kraigher E, Filippatos G, Butler J, et al. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study. Eur Heart J. 2017;38(15):1119–27.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gheorghiade M, Greene SJ, Butler J, Filippatos G, Lam CS, Maggioni AP, et al. Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: the SOCRATES-REDUCED randomized trial. JAMA. 2015;314(21):2251–62.

Article  CAS  PubMed  Google Scholar 

Bonderman D, Pretsch I, Steringer-Mascherbauer R, Jansa P, Rosenkranz S, Tufaro C, et al. Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1): a randomized, double-blind, placebo-controlled, single-dose study. Chest. 2014;146(5):1274–85.

Article  PubMed  PubMed Central  Google Scholar 

Ghofrani H-A, Galiè N, Grimminger F, Grünig E, Humbert M, Jing Z-C, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013;369(4):330–40.

Article  CAS  PubMed  Google Scholar 

Ghofrani H-A, D’Armini AM, Grimminger F, Hoeper MM, Jansa P, Kim NH, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med. 2013;369(4):319–29.

Article  CAS  PubMed  Google Scholar 

Bonderman D, Ghio S, Felix SB, Ghofrani H-A, Michelakis E, Mitrovic V, et al. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. Circulation. 2013;128(5):502–11.

Article  CAS  PubMed  Google Scholar 

Tran N, Garcia T, Aniqa M, Ali S, Ally A, Nauli SM. Endothelial Nitric Oxide Synthase (eNOS) and the Cardiovascular System: in Physiology and in disease states. Am J Biomed Sci Res. 2022;15(2):153–77.

CAS  PubMed  PubMed Central  Google Scholar 

Sharma R, Davidoff MN. Oxidative stress and endothelial dysfunction in heart failure. Congest Heart Fail. 2002;8(3):165–72. https://doi.org/10.1111/j.1527-5299.2002.00714.x.

Article  CAS  PubMed  Google Scholar 

Stamerra CA, Di Giosia P, Giorgini P, Ferri C, Sukhorukov VN, Sahebkar A. Mitochondrial dysfunction and cardiovascular disease: pathophysiology and emerging therapies. Oxid Med Cell Longev. 2022;2(2022):9530007.

Google Scholar 

Gianni D, Chan J, Gwathmey JK, Del Monte F, Hajjar RJ. SERCA2a in heart failure: role and therapeutic prospects. J Bioenerg Biomembr. 2005;37(6):375–80.

Article  CAS  PubMed  Google Scholar 

Franssen C, Chen S, Unger A, Korkmaz HI, De Keulenaer GW, Tschöpe C, et al. Myocardial microvascular inflammatory endothelial activation in heart failure with preserved ejection fraction. JACC Heart Fail. 2016;4(4):312–24.

Article  PubMed  Google Scholar 

van Heerebeek L, Hamdani N, Falcão-Pires I, Leite-Moreira AF, Begieneman MP, Bronzwaer JG, van der Velden J, Stienen GJ, Laarman GJ, Somsen A, Verheugt FW, Niessen HW, Paulus WJ. Low myocardial protein kinase G activity in heart failure with preserved ejection fraction. Circulation. 2012;126(7):830–9.

Article  PubMed  Google Scholar 

Gheorghiade M, Marti CN, Sabbah HN, Roessig L, Greene SJ, Böhm M, et al. Soluble guanylate cyclase: a potential therapeutic target for heart failure. Heart Fail Rev. 2013;18(2):123–34.

Article  CAS  PubMed  Google Scholar 

Schulz E, Jansen T, Wenzel P, Daiber A, Münzel T. Nitric oxide, tetrahydrobiopterin, oxidative stress and endothelial dysfunction in hypertension. Antioxid Redox Sig. 2008;10:1115–26.

Article  CAS  Google Scholar 

Calderone A, Thaik CM, Takahashi N, Chang DL, Colucci WS. Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth promoting effects of norepinephrine in cardiac myocytes and fibroblasts. J Clin Invest. 1998;101:812–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fiedler B, Lohmann SM, Smolenski A, Linnemuller S, Pieske B, Schroder F, Molkentin JD, Drexler H, Wollert KC. Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes. Proc Natl Acad Sci U S A. 2002;99:11363–8.

Article